NCT02972840 2026-02-18A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCLAcerta Pharma BVPhase 3 Active not recruiting635 enrolled 1 FDA
NCT02213926 2026-02-10An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell LymphomaAcerta Pharma BVPhase 2 Active not recruiting124 enrolled 10 charts 1 FDA